CDK Inhibitor Compounds for Diverse Therapeutic and Cosmetic Applications
Legal Citation
Summary of the Inventive Concept
The inventive concept discloses novel applications and use cases of 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds as CDK inhibitors, expanding their therapeutic potential beyond cancer treatment to neurological disorders, inflammation reduction, veterinary care, diagnostic biomarker detection, and cosmetic skin health promotion.
Background and Problem Solved
The original patent disclosed CDK inhibitor compounds for cancer treatment, but their potential therapeutic benefits were limited to this specific application. The inventive concept addresses the problem of underutilization of these compounds by exploring new applications and use cases, thereby increasing their therapeutic and commercial value.
Detailed Description of the Inventive Concept
The inventive concept comprises novel formulations, delivery systems, and compositions of the CDK inhibitor compounds, adapted for transdermal delivery, topical administration, veterinary care, diagnostic biomarker detection, and cosmetic skin health promotion. Specifically, the claims include a system for treating neurological disorders via transdermal delivery, a method for reducing inflammation using topical creams or ointments, a pharmaceutical composition for veterinary use, a diagnostic kit for detecting CDK-related biomarkers, and a cosmetic product for promoting skin health.
Novelty and Inventive Step
The inventive concept's novelty lies in its unexpected application of CDK inhibitor compounds to diverse therapeutic and cosmetic areas, which was not obvious from the original patent. The inventive step involves the recognition of the compounds' broader therapeutic potential and the development of novel formulations, delivery systems, and compositions to realize this potential.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept may include oral, injectable, or implantable formulations, as well as combinations with other therapeutic agents or biomarkers. Variations may involve the use of different CDK inhibitor compounds or analogs, or the development of new diagnostic biomarkers or cosmetic products.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in various industries, including pharmaceuticals, veterinary care, diagnostics, and cosmetics. The expanded therapeutic and cosmetic applications of the CDK inhibitor compounds are expected to increase their market value and attract new customers, partners, and investors.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical chemistry, specifically medicinal chemistry focused on CDK inhibitors, drug delivery systems, and therapeutic applications across multiple medical domains
Person of Ordinary Skill (PHOSITA) Profile
A researcher with a PhD in medicinal chemistry or pharmacology, experienced in drug design, formulation strategies, and understanding structure-activity relationships for small molecule inhibitors
Obviousness Rationale
A PHOSITA would recognize that CDK inhibitor compounds have broad potential therapeutic applications beyond their initial cancer treatment context. The disclosed variations represent predictable extensions of the source patent's core compound structure by applying known drug delivery and formulation techniques to explore alternative medical uses. The technical modifications represent routine optimization and exploration of a known compound's potential therapeutic range.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,552 |
|---|---|
| Title | 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds as CDK inhibitors |
| Assignee(s) | CARRICK THERAPEUTICS LIMITED |